attIL2-T cells

Phase 1Small molecule

MM.D. Anderson Cancer Center

attIL2-T cells is one of 23 small molecule programs targeting Bone Sarcoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bone SarcomaActive, not recruiting

Bone SarcomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Bone Sarcoma

#DrugCompanyPhaseTrials

Afinitor

Novartis

Approved

—2

Trexall

Alnylam Pharmaceuticals

Phase 2

2 3

DTIC-Dome

Bayer

Phase 2

2 4

Ridaforolimus

Votrient

1 6

Stivarga

Bayer

Phase 2

1 7

Adriamycin

Pfizer

Phase 2

1 8

Ellence

Pfizer

Phase 2

1 9

Sutent

Pfizer

Phase 2

1 10

Opdivo

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Bone Sarcoma

NCT05621668

Clinical

Trials by Indication[1]

Bone Sarcoma1 trial

A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05621668·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for attIL2-T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — attIL2-T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for attIL2-T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MM.D. Anderson Cancer Center

attIL2-T cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Bone Sarcoma1 trial

References

Drug Info

Quick Facts

Related News